Tavapadon

Overview

Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Expanded Access to Tavapadon	2025/09/08	NCT07158827	N/A	AVAILABLE	AbbVie
A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants	2025/03/26	NCT06895356	Phase 1	Completed	AbbVie
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease	2022/11/09	NCT05610189	Phase 1	Completed	Cerevel Therapeutics, LLC
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants	2022/10/17	NCT05581823	Phase 1	Completed	Cerevel Therapeutics, LLC
To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function	2022/06/03	NCT05404529	Phase 1	Completed	Cerevel Therapeutics, LLC
To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function	2022/06/03	NCT05404542	Phase 1	Completed	Cerevel Therapeutics, LLC
Open-label Trial in Parkinson's Disease (PD)	2021/02/18	NCT04760769	Phase 3	Active, not recruiting	AbbVie
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)	2020/09/09	NCT04542499	Phase 3	Completed	AbbVie
A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease	2020/03/04	NCT04295642	Phase 1	Completed	Cerevel Therapeutics, LLC
An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects	2020/01/27	NCT04241393	Phase 1	Completed	Cerevel Therapeutics, LLC

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Tavapadon Shows Promise in Phase 3 Trials for Parkinson's Disease with Improved Motor Function and Safety Profile

6 months ago

The TEMPO-1 and TEMPO-2 trials demonstrated that tavapadon, a selective D1/D5 dopamine receptor agonist, significantly improved motor function in newly diagnosed Parkinson's disease patients compared to placebo.

AbbVie's Skyrizi and Rinvoq Gain Market Share as Company Navigates Post-Humira Landscape

9 months ago

AbbVie reports significant market penetration for Skyrizi and Rinvoq in IBD indications, capturing approximately 50% market share in Crohn's disease and ulcerative colitis treatment spaces.

AbbVie Reassesses Emraclidine's Future After Phase II Schizophrenia Trial Failures

9 months ago

AbbVie's emraclidine failed to meet primary endpoints in Phase II trials for schizophrenia, leading to a $3.5 billion impairment charge and a reevaluation of its development path.

Key Advances in Neuromuscular and Movement Disorder Treatments Highlighted in 2024

10 months ago

• AbbVie's Vyalev, a 24-hour subcutaneous levodopa infusion, gained FDA approval for managing motor fluctuations in advanced Parkinson's, offering a novel therapeutic approach. • Intellia's CRISPR therapy, NTLA-2001, demonstrated safe redosing in ATTR amyloidosis patients, achieving additive pharmacodynamic effects on the target protein. • A phase 3 study revealed that buntanetap is a safe and well-tolerated drug which improves motor, nonmotor, and cognitive symptoms of Parkinson's disease. • The FDA supported using αSyn-SAA biomarker in Parkinson's clinical trials, enhancing therapeutic development through improved diagnostic precision.

AbbVie's Tavapadon Shows Positive Phase 3 Results for Parkinson's Disease